Free tool
Find any stock
Search all ~22,000 companies we cover across the US, Europe and Asia-Pacific, or browse them market by market — then open any one of them for the full analysis.
Search all ~22,000 companies we cover across the US, Europe and Asia-Pacific, or browse them market by market — then open any one of them for the full analysis.
Search all ~22,000 companies we cover across the US, Europe and Asia-Pacific, or browse them market by market — then open any one of them for the full analysis.
105 stocks worldwide match these filters · market cap, largest first. Clear filters
Data as of Aug 27, 2026 · updates nightly, Mon–Sat
| Ticker | Company | Theme | Market cap (USD) | Price | vs 52-week high | 1M return |
|---|---|---|---|---|---|---|
| SEPN | Septerna, Inc. | Rare disease | $1.88B | $40.25 | −21.23% | +18.49% |
| NEU.AX | Neuren Pharmaceuticals Limited | Rare disease | $1.88B | 20.59 AUD | −13.34% | +20.20% |
| ETON | Eton Pharmaceuticals, Inc. | Rare disease | $1.79B | $62.62 | −5.65% | +34.20% |
| ANAB | AnaptysBio, Inc. | Rare disease |
Every company we cover sits in at least one of these lists. Each one opens as a full table of its members, ordered by market value.
The 11 business sectors every covered company is classified into.
The 20 narrower groupings we keep for parts of the market that do not split neatly by sector.
Price chart, technicals, money flow, fundamentals and an AI-written read — one page per stock, $9.90 each. Already know the symbol?
| $1.73B |
| $58.00 |
| −19.85% |
| +11.30% |
| ANIP | ANI Pharmaceuticals, Inc. | Rare disease | $1.71B | $74.56 | −25.07% | −8.00% |
| 0L35.L | Sarepta Therapeutics, Inc. | Rare disease | $1.69B | $18.51 | −26.95% | +1.60% |
| MAZE | Maze Therapeutics, Inc. | Rare disease | $1.69B | $29.58 | −44.86% | +6.10% |
| AVLN | Avalyn Pharma Inc. | Rare disease | $1.64B | $37.04 | −7.79% | +33.29% |
| FBRX | Forte Biosciences, Inc. | Rare disease | $1.63B | $76.99 | −0.27% | +0.44% |
| PYC.AX | PYC Therapeutics Limited | Rare disease | $1.60B | 2.25 AUD | −1.32% | +38.46% |
| XERS | Xeris Biopharma Holdings, Inc. | Rare disease | $1.58B | $8.68 | −13.89% | +5.34% |
| TRAX | First Tracks Biotherapeutics, Inc. | Rare disease | $1.58B | $44.19 | −11.46% | +5.59% |
| A2RR34.SA | Arrowhead Pharmaceuticals, Inc. | Rare disease | $1.58B | 57.60 BRL | −3.92% | +8.15% |
| TYRA | Tyra Biosciences, Inc. | Rare disease | $1.56B | $26.22 | −35.50% | −15.09% |
| 4516.T | Nippon Shinyaku Co., Ltd. | Rare disease | $1.52B | 3,588.00 JPY | −45.05% | +1.07% |
| KALV | KalVista Pharmaceuticals Inc | Rare disease | $1.44B | $27.00 | 0.00% | 0.00% |
| 0LIF.L | Ultragenyx Pharmaceutical Inc. | Rare disease | $1.40B | $26.19 | −36.89% | +1.39% |
| OMER | Omeros Corporation | Rare disease | $1.40B | $18.22 | −7.28% | +61.52% |
| JBIO | Jade Biosciences, Inc. | Rare disease | $1.39B | $21.33 | −23.82% | +8.27% |
| MLTX | MoonLake Immunotherapeutics | Rare disease | $1.32B | $15.62 | −75.11% | −16.52% |
| 0HB0.L | Agios Pharmaceuticals, Inc. | Rare disease | $1.19B | $34.05 | −25.68% | +0.18% |
| SVRA | Savara Inc. | Rare disease | $1.15B | $5.61 | −19.91% | +5.25% |
| AVTX | Avalo Therapeutics, Inc. | Rare disease | $1.10B | $20.55 | −15.33% | +5.28% |
| 006280.KS | GC Biopharma Corp. | Rare disease | $1.06B | 127,100.00 KRW | −30.85% | +12.28% |
| WVE | Wave Life Sciences, Inc. | Rare disease | $1.03B | $5.23 | −75.93% | −11.21% |
| DSGN | Design Therapeutics, Inc. | Rare disease | $975.65M | $15.59 | −9.62% | +31.34% |
| ANNX | Annexon, Inc. | Rare disease | $946.00M | $4.99 | −30.50% | +0.40% |
| DBVT | DBV Technologies S.A. | Rare disease | $940.80M | $14.52 | −44.55% | +7.56% |
| CLYM | Climb Bio Inc | Rare disease | $923.57M | $16.08 | −12.27% | +30.84% |
| DBV.PA | DBV Technologies S.A. | Rare disease | $901.25M | 2.53 EUR | −43.78% | +5.42% |
| PHAR | Pharming Group N.V. | Rare disease | $845.80M | $11.95 | −44.00% | −7.08% |
| SLN | Silence Therapeutics plc | Rare disease | $840.94M | $13.53 | −23.02% | +17.14% |
| GNFT.PA | Genfit S.A. | Rare disease | $830.56M | 14.30 EUR | −5.92% | +5.30% |
| STTK | Shattuck Labs, Inc. | Rare disease | $792.87M | $7.90 | −5.16% | +15.84% |
| 0QNA.L | Basilea Pharmaceutica AG | Rare disease | $762.45M | 65.80 CHF | −1.05% | +2.73% |
| ASMB | Assembly Biosciences, Inc. | Rare disease | $721.17M | $35.42 | −10.80% | +38.52% |
| IRWD | Ironwood Pharmaceuticals, Inc. | Rare disease | $708.88M | $4.29 | −25.78% | +12.89% |
| GYRE | Gyre Therapeutics, Inc. | Rare disease | $705.12M | $6.65 | −29.41% | +11.02% |
| AGMB | AgomAb Therapeutics NV | Rare disease | $703.26M | $14.28 | −19.87% | +13.88% |
| TECX | Tectonic Therapeutic, Inc. | Rare disease | $703.19M | $35.97 | −9.01% | +20.70% |
| ZVRA | Zevra Therapeutics, Inc. | Rare disease | $697.17M | $11.74 | −21.92% | +20.66% |
| AQST | Aquestive Therapeutics, Inc. | Rare disease | $676.51M | $5.39 | −28.61% | +43.35% |
| CRMD | CorMedix Inc. | Rare disease | $653.95M | $8.39 | −43.92% | +14.15% |
| VALN | Valneva SE | Rare disease | $634.84M | $6.70 | −45.26% | +32.31% |
| AYJ.DE | Valneva SE | Rare disease | $619.77M | 2.98 EUR | −43.20% | +35.29% |
| 0KBU.L | Omeros Corporation | Rare disease | $575.28M | $18.44 | −5.99% | −4.75% |
| ZURA | Zura Bio Limited | Rare disease | $574.02M | $5.99 | −19.49% | +8.12% |
| SPRY | ARS Pharmaceuticals, Inc. | Rare disease | $568.84M | $6.03 | −59.72% | +6.35% |
| 005257.KS | GC Corp. | Rare disease | $547.34M | 16,630.00 KRW | −47.54% | +20.51% |
| EPRX | Eupraxia Pharmaceuticals Inc. | Rare disease | $490.26M | $7.43 | −20.28% | +21.80% |
| EPRX.TO | Eupraxia Pharmaceuticals Inc. | Rare disease | $487.17M | 10.28 CAD | −20.06% | +20.23% |
| RZLT | Rezolute, Inc. | Rare disease | $485.31M | $5.04 | −56.01% | +2.44% |
| KMDA | Kamada Ltd. Ordinary Shares | Rare disease | $483.48M | $8.38 | −10.37% | +18.70% |
| QTTB | Q32 Bio Inc. | Rare disease | $481.67M | $16.18 | −31.35% | +2.99% |
| AVIR | Atea Pharmaceuticals, Inc. | Rare disease | $441.93M | $5.51 | −14.57% | +22.17% |
| LRMR | Larimar Therapeutics, Inc. | Rare disease | $432.15M | $4.17 | −35.05% | +8.88% |
| XFOR | X4 Pharmaceuticals, Inc. | Rare disease | $412.45M | $4.17 | −13.66% | +6.11% |
| ENTA | Enanta Pharmaceuticals, Inc. | Rare disease | $412.12M | $14.15 | −17.49% | +12.21% |
| 4552.T | JCR Pharmaceuticals Co., Ltd. | Rare disease | $406.58M | 531.00 JPY | −35.56% | +2.71% |
| UPB | Upstream Bio, Inc. | Rare disease | $390.52M | $7.13 | −78.83% | +11.41% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.
Size bands, from the largest companies down to the smallest we cover.
The 23 listing venues our coverage spans, across the Americas, Europe and Asia-Pacific.
5 lists built on a single stated criterion, such as paying a dividend or trading near a 52-week high.
The largest one day percentage moves in either direction, among the mid, large and mega cap companies we cover.